ABSTRACT
Introduction
The introduction of high-dose therapy and the novel agents thalidomide, bortezomib and lenalidomide have improved complete response rates and doubled multiple myeloma (MM) patients' survival, 1 but unfortunately the majority of patients relapse. In MM, relapses have been attributed to MM Cancer Stem Cells (MM-CSC), although inconsistencies have emerged with respect to their frequency, clonogenicity and phenotype. [2] [3] [4] [5] It has been proposed that CD20 could be a hallmark of MM-CSC. In support of this hypothesis, Matsui et al. have shown the capacity of the anti-CD20 MoAb rituximab to inhibit the clonogenic growth of MM-CSC in vitro. 3, 6 However, clinical trials to test the effect of rituximab as maintenance therapy have failed to confirm a survival benefit. 7, 8 Furthermore, data from other groups do not support the hypothesis that B cells are the feeder cells in myeloma. 9, 10 In order to shed some light on this controversial area, we have searched for the presence and functionality of CD20 + putative MM-CSC in a panel of MM cell lines.
Design and Methods
The human MM cell lines used were: RPMI-8226 and U266 (from Dr W Dalton, Tampa, FL, USA); MM1S and MM1R (from Dr ST Rosen, Chicago, IL, USA); NCI-H929 (from Dr J Teixidó, Madrid, Spain); RPMI-LR5, U266-LR7 and U266-Dox4 (from Dr KC Anderson, Boston, MA, USA). The cells were cultured as previously described. 11 Briefly, the cells were cultured in RPMI-1640 medium supplemented with 2 mM L-glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin and 10% fetal bovine serum at 37°C and 5% CO2/95% air.
MM cell lines were immunophenotyped using a 7-color immunofluorescence technique, 12 with the following combination of monoclonal antibodies (Pacific Blue (PB)/ anemonia majano cyan (AmCyan)/ fluorescein isothiocyanate (FITC)/ peridinin chlorophyll protein-cyanin 5.5 (PerCP-Cy5.5)/ PE-cyanin 7 (PE-Cy7)/ allophycocyanin (APC)/ alexafluor 700 (AF700)): CD19/CD45/CD20/CD138/CD27/CD56/CD38. Data were stored for a minimum of 3¥10 5 events. CD20 dim+ and CD20 -RPMI-8226 cells were sorted after incubation with CD20-APC/7AAD and acquisition on a FACSAria cytometer (Becton Dickison Biosciences). Sorting was performed only for viable cells (7AAD -) and debris were excluded by scatter properties. The CD20 -and CD20 dim+ RPMI-8226 sorted cells had a mean final purity of over 99% and 88%, respectively. The origin of the monoclonal antibodies was as follows: CD20-FITC (clone L27), CD20-APC (clone L27), CD138-PerCP-Cy5 (clone MI15), CD56-APC (clone NCAM16.2) and CD45-AmCyan (clone 2D1) were obtained from BD Biosciences (San Jose, CA, USA); CD19-PacificBlue (clone CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype dim+ and CD20 -RPMI-8226 cells using an RNeasy Mini Kit (Qiagen, Valencia, USA) following the manufacturer's protocol. RNA quality and quantity were assessed with the RNA Nano LabChip (Agilent Tech. Inc., Palo Alto, CA, USA). The retrotranscription reaction was performed with a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems Foster City, CA, USA) according to the manufacturer's recommendations. Finally, real time quantitative PCR was performed using TaqMan gene expression assay kits (Applied Biosystems Foster City, CA, USA): Hs_00544819 for MS4A1 (CD20) and Hs99999905_m1 GAPDH as a control gene. Relative gene expression was calculated by the 2 -ΔCt method, ΔCt=Ct (gene) -Ct (GAPDH). Morphological characterization was performed with May-Grünwald-Giemsa staining. May-Grünwald and Giemsa stains were obtained from Merck (Darmstadt, Germany). Characterization of VDJH and IGκ rearrangements was performed in genomic cDNA as described elsewhere. 13 The expression of aldehyde dehydrogenase (ALDH) was assessed using the Aldefluor Kit (StemCell Technologies, Grenoble, France) following the manufacturer's instructions with further staining with a CD20-APC antibody. For microarray studies, RNA from 3 independent CD20 dim+ or CD20 -RPMI-8226 samples was isolated, labeled and hybridized to Human Gene 1.0 ST array (Affymetrix) according to Affymetrix protocols. 14 The arrays were analyzed using the DNA-Chip Analyzer software (DChip). Fold change of 2 or more was considered significant. All microarray data have been deposited with the Gene Expression Omnibus under accession number GSE33020.
For serial colony assays, 1000-1500 CD20 dim+ or CD20 -RPMI-8226 cells/mL were plated in Methocult ® (StemCell Technologies, catalog n. H4230) and incubated at 37°C and 5% CO2. After 14 days, colonies (≥40 cells) were scored and subsequently collected, rinsed with PBS and plated again in fresh Methocult ® . A sample was used to evaluate CD20 expression in the colonies. For engrafting assays, unfractionated or sorted CD20 dim+ or CD20 -RPMI-8226 cells were subcutaneously inoculated into 6-7 week old CB17-SCID mice (Charles River, Spain). 11 In selected mice, tumors were isolated, mechanically minced and filtered through 40 µm cellstrainers to perform phenotypic studies and/or reinjection into secondary recipients. All animal experiments were performed according to the protocol previously approved by the ethical committee of the University of Salamanca, Spain.
Statistical analyses were performed using the SPSS-15.0 software (SPSS, Chicago, IL, USA); significant differences between groups were assessed by the Student's t and Mann-Whitney U tests.
Results and Discussion
One decade ago, several reports suggested the existence in MM of circulating clonotypic B cells that displayed drug resistance and could be responsible for spreading the disease, leading to their definition as putative MM-CSC. + MM-CSC in two MM cell lines and in patient samples. 3, 6 Furthermore, their clonogenic growth was inhibited by the anti-CD20 MoAb rituximab. 3, 6 To confirm these results and to investigate MM-CSC more deeply, we examined the presence and characteristics of CD20 + cells in a panel of drug sensitive (RPMI-8226, MM1S, U266, NCI-H929) and resistant (RPMI-LR5, MM1R, U266-LR7, U266-Dox4) MM cell lines. In all except one (RPMI-8226), CD20 + cells were undetectable by flow cytometry with a sensitivity of 7¥10 -5 ( Figure  1A) . 16 In line with our results, Rossi et al. reported that U266, NCI-H929 and MM1R cell lines are CD20 -17 while Matsui et al. described a small population (2-5%) of CD138 -CD20
+ cells in the NCI-H929 and RPMI-8226 cell lines. 3 In our hands, the RPMI-8226 cell line included a small CD20 dim+ subset (0.3%) ( Figure 1A ). Data from qRT-PCR confirmed a significant higher expression of CD20 in the CD20 dim+ RPMI-8226 cells with respect to the CD20 -RPMI-8226 cells ( Figure 1B) . Furthermore, the CD20 dim+ subset displayed a myelomatous plasma cell phenotype:
-( Figure  1C ). 16 Therefore, we did not confirm the B-cell phenotype of the putative CD20 + MM-CSC. Morphologically, CD20 dim+ RPMI-8226 cells showed a higher number of vacuoles and a more relaxed chromatin ( Figure 1D ) suggesting that they represent a more immature compartment which would be concordant with data describing CD20 expression in MM associated with a plasmablast morphology. 18 The expression of molecules related to drug resistance and self-renewal is a CSC-hallmark. Here we analyzed the expression of the MM-CSC marker ALDH 6, 19 in CD20 dim+ and CD20 -RPMI-8226 cells and we did not find overexpression of ALDH in the CD20 dim+ versus the CD20 -fraction ( Figure 1E ). To investigate other potential CSC-markers, we next studied the gene expression profile of CD20 dim+ RPMI-8226 cells. This showed 48 genes up-regulated and one gene down-regulated versus CD20 -RPMI-8226 cells (Online Supplementary Table S1 ). It should be mentioned that, among the 48 up-regulated genes, MS4A1, the CD20-encoding gene, displayed the highest fold change (37.27). When we focused on MM-CSCassociated genes such as Hedgehog, 20 ABCG2 21 and SOX2 19 they were not expressed in CD20 dim+ RPMI-8226 cells. Interestingly, the Notch-target gene, Hes1, was overexpressed in CD20 dim+ RPMI-8226 cells (Online Supplementary Table S1 ). Although Hes genes have been generally associated with stem cell maintenance, this is apparently not the case for MM where Notch1 activation is related to growth inhibition and apoptosis. 22 Finally, in vitro and in vivo functional characterization was tackled. Therefore both, CD20 dim+ and CD20 -RPMI-8226 cells, formed colonies after 6 rounds of replating ( Figure 2A ) suggesting their long-term proliferation capacity. Since differentiation potential is another characteristic of cancer stem cells, whether CD20 dim+ cells give rise to CD20 -cells or vice versa was studied during serial colony assays. We were, therefore, able to observe that the population of CD20 -cells, initially sorted and plated (plating 1, P1) with a purity of over 99%, gave rise to CD20 dim+ cells: 15% in plating 2 (P2), 36% in plating 3 (P3) and 50% in plating 4 (P4) ( Figure 2B ). Conversely, CD20 dim+ RPMI-8226 cells, initially sorted and plated (P1) with a purity of 90%, did not seem to differentiate into CD20 -cells since CD20 is not a stem marker in myeloma cell lines haematologica | 2012; 97(7) 1111
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there was no great variation in the percentage of CD20 dim+ cells (80%, 98% and 95% in P2, P3 and P4, respectively) ( Figure 2B ). Therefore, these data indicate a hierarchical order in which CD20 dim+ cells derive from CD20 -cells. It is well-known that RPMI-8226 cells promote plasmacytomas in SCID mice. 23 However, whether this is due to a haematologica | 2012; 97(7) 0  1E3  1E4  1E5  0  1E3  1E4  1E5   CD19  CD27  CD38  CD45  CD56  CD138   CD19  CD27  CD38  CD45  CD56  CD138   +DEAB  -DEAB   CD20   -CD20 unfractionated (n=4) or CD20 depleted (n=4) RPMI-8226 cells into 8 CB17-SCID mice. We found that 100% of the mice in each group developed plasmacytomas without any difference in the growth pattern ( Figure 2C ), suggesting that CD20 dim+ cells are not essential for tumor formation. Nevertheless, since serial transplantation is the only in vivo assay to functionally measure stem cell self-renewal capacity, 24 CB17-SCID mice were first injected with either CD20
-or CD20 dim+ RPMI-8226 cells (primary tumors) and, subsequently, secondary mice were injected with cells isolated from either a CD20 -or a CD20 dim+ derived tumor (secondary tumors) ( Figure 2D , left). Despite differences in the primary engrafting capacity for CD20 -and CD20 dim+ cells (25% and 50%, respectively), a high variability in tumor growth curves was observed ( Figure 2D, top right) . However, whereas sorted CD20 dim+ cells formed secondary tumors only in 25% of mice, sorted CD20
-cells formed secondary tumors in 100% of the mice and, furthermore, the latter grew faster ( Figure 2D , bottom right). These results suggest that CD20 -RPMI-8226 cells have higher self-renewal capacity than CD20 dim+ cells and do not support CD20 as a marker of MM-CSC. 3, 6 In fact, we found that more than 99% of cells isolated from primary tumors were negative for CD20 even when CD20 dim+ cells had been injected ( Figure  2E ). Nevertheless, it would be interesting to carry out further experiments of serial dilution and subsequent transplantation of CD20 dim+ and CD20 -RPMI-8226 cells in order to evaluate the tumor-initiating ability of each fraction quantitatively.
In conclusion, our results show that CD20 is undetectable in the majority of MM cell lines. Additionally, the expression of CD20 in the RPMI-8226 cell line is not associated with a cancer stem cell phenotype. Therefore, our results do not support CD20 + expression for the identification of MM-CSC. 
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